Stockscreener 앱 받기
18.58
0.09%
0.0436
전일 마감가:
$18.54
열려 있는:
$18.54
하루 거래량:
170.28K
Relative Volume:
0.23
시가총액:
$1.52B
수익:
$288.00K
순이익/손실:
$-228.06M
주가수익비율:
-4.3726
EPS:
-4.25
순현금흐름:
$-168.82M
1주 성능:
+9.87%
1개월 성능:
+12.33%
6개월 성능:
+17.08%
1년 성능:
+19.80%
1일 변동 폭
$18.54
$18.96
1주일 범위
$16.95
$19.10
52주 변동 폭
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
명칭
Viridian Therapeutics Inc
전화
617.272.4600
주소
221 CRESCENT STREET, WALTHAM
VRDN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
18.57 | 1.51B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.35 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.22 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
455.66 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
662.15 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
327.29 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 개시 | TD Cowen | Buy |
| 2024-09-11 | 재확인 | Needham | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-05-09 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | 개시 | BTIG Research | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-05-30 | 개시 | RBC Capital Mkts | Outperform |
| 2023-04-17 | 개시 | Wells Fargo | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2022-12-19 | 개시 | Cowen | Outperform |
| 2022-12-19 | 개시 | Needham | Buy |
| 2022-12-16 | 개시 | Credit Suisse | Outperform |
| 2022-12-01 | 개시 | H.C. Wainwright | Buy |
| 2022-06-23 | 개시 | B. Riley Securities | Buy |
| 2021-11-18 | 개시 | SVB Leerink | Outperform |
| 2021-10-12 | 개시 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
Viridian Therapeutics, Kissei Pharmaceutical Partner for Japanese Development of Thyroid Eye Disease Therapies, Securing $70M Upfront - Yahoo Finance
Published on: 2025-08-17 06:00:45 - metal.it
Published on: 2025-08-16 03:42:15 - sundaytimes.kr
Published on: 2025-08-14 03:20:38 - beatles.ru
Will Viridian Therapeutics Inc. Bounce From 52 Week LowMarket Risk Report & Stepwise Trade Execution Plans - beatles.ru
RBC Capital Initiates Viridian Therapeutics(VRDN.US) With Buy Rating, Announces Target Price $41 - 富途牛牛
Published on: 2025-08-14 00:53:45 - 선데이타임즈
Evercore ISI Maintains Buy Rating on Viridian Therapeutics with $38 Price Target - AInvest
Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating - TipRanks
Viridian Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail
Goldman Sachs Raises Price Target for Viridian Therapeutics (VRDN) to $30: Analysts' Forecasts and Ratings. - AInvest
Viridian Therapeutics Q2 Results Beat Expectations, Analysts Revise Forecasts - AInvest
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results - Benzinga
Oppenheimer Boosts Viridian Therapeutics' Target Price to $32.00, Maintaining 'Outperform' Rating. - AInvest
Wells Fargo Lowers Viridian Therapeutics Price Target to $26, Keeps Equal Weight Rating - AInvest
Viridian: Oppenheimer raises PT to $32 from $28, maintains Outperform rating. - AInvest
RBC Lowers Price Target on Viridian Therapeutics to $41 From $45, Keeps Outperform, Speculative Risk - MarketScreener
Viridian Therapeutics price target lowered to $26 from $27 at Wells Fargo - TipRanks
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Viridian Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments - TipRanks
Viridian (VRDN) Reports Q2 Revenue Surpassing Estimates, Cash Position Supports Operations into 2027. - AInvest
Viridian Therapeutics Grants Inducement Stock Options to New Employees - AInvest
Viridian Therapeutics: Hold Rating and Awaited 2026 Developments - AInvest
Viridian 2025 Q2 Earnings Wider Losses Amid Regulatory and Partnership Momentum - AInvest
Viridian Therapeutics: Strong Financial Position and Promising Pipeline Support Buy Rating - TipRanks
Viridian (VRDN) Q2 Net Loss Widens 55% - AOL.com
Viridian Therapeutics: Promising Future with Strong Financials and Strategic Developments - TipRanks
Viridian Therapeutics: Promising Outlook with Positive Phase 3 Data and Strategic Licensing Agreements - TipRanks
Viridian Therapeutics Q2 Net Loss Widens, Revenue Increases - MarketScreener
Viridian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - BioSpace
Viridian Therapeutics Rises With Strong Cash And Clinical Progress - Finimize
Viridian Therapeutics, Inc.\DE SEC 10-Q Report - TradingView
Viridian Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Viridian Therapeutics Q2 2025 Financial Results - TradingView
Earnings Flash (VRDN) Viridian Therapeutics, Inc. Reports Q2 Revenue $75,000, vs. FactSet Est of $100,000 - MarketScreener
Earnings Flash (VRDN) Viridian Therapeutics Posts Q2 Net Loss $1.00 a Share, vs. FactSet Est of $1.00 Loss - MarketScreener
Viridian Therapeutics shares rise 3.86% intraday after announcing inducement grants to new employees. - AInvest
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 - BioSpace
Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
What makes Viridian Therapeutics Inc. stock price move sharplyGet expert insights on market-moving stocks - Jammu Links News
When is Viridian Therapeutics Inc. stock expected to show significant growthStrong return on assets - Jammu Links News
What are the latest earnings results for Viridian Therapeutics Inc.Breakout portfolio performance - Jammu Links News
What is Viridian Therapeutics Inc. company’s growth strategyUnlock daily market insights for better trades - Jammu Links News
Is Viridian Therapeutics Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News
Is it the right time to buy Viridian Therapeutics Inc. stockAchieve consistent high returns with low risk - Jammu Links News
What analysts say about Viridian Therapeutics Inc. stockExplosive trading growth - Jammu Links News
How does Viridian Therapeutics Inc. compare to its industry peersMarket-leading capital gains - Jammu Links News
Why is Viridian Therapeutics Inc. stock attracting strong analyst attentionGet expert insights on market-moving stocks - Jammu Links News
What is the dividend policy of Viridian Therapeutics Inc. stockUnprecedented profit potential - Jammu Links News
Viridian Therapeutics Inc (VRDN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.30%
자본화:
|
볼륨(24시간):